Amalgam Rx Competitive Intelligence & Landscape
amalgamrx.com ·
Overview
Amalgam Rx Overview
The company's core products include AI-powered digital health tools, integrated into clinical workflows and patient daily lives, supporting nearly 10 million patients across four continents and enabling over 70 million clinical decisions (Exa, amalgamrx.com). Its solutions are designed for global life sciences companies, health plans, and healthcare providers, with a focus on digital therapeutics (DTx), clinical decision support, and patient engagement. The company’s mission is to reimagine care delivery by leveraging advanced AI and digital health technologies to improve health outcomes.
With approximately 49 employees and recent funding rounds totaling over $46 million, Amalgam Rx continues to expand its market presence and technological capabilities. Its strategic focus includes developing digital therapeutics, companion products, and EHR-integrated solutions to facilitate better clinical and patient outcomes, positioning itself as a key player in the digital health and AI-driven healthcare space (Exa, amalgamrx.com).
Amalgam Rx Weekly Intel Updates
Receive weekly intel updates about Amalgam Rx straight to your inbox.
Competitors
Amalgam Rx Competitors
Premier operates primarily as a healthcare services provider with a focus on clinical and administrative solutions, offering a broad range of services that include revenue cycle management and clinical data integration. Its market positioning is more service-oriented compared to Amalgam Rx’s digital platform focus, and it commands a significant share in healthcare operations, especially among hospital systems (CB Insights). While Amalgam Rx emphasizes digital health solutions, Premier’s strength lies in its extensive healthcare network and operational services, making it a strong indirect competitor in terms of market reach and integration capabilities (CB Insights).
Better, established in 1989 and based in Slovenia, offers a broad digital health platform that includes electronic prescribing, low-code development tools, and medication management, positioning itself as a comprehensive digital health solution provider. Compared to Amalgam Rx, Better has a longer market presence and a larger team, with a focus on healthcare decision-making and provider workflow optimization, which could appeal to a broader range of healthcare providers and payers (BounceWatch). While Amalgam Rx is more specialized in digital health solutions, Better’s extensive service offerings and longer history give it a competitive edge in market share and trust within the healthcare industry (BounceWatch).
Tebra, a leading e-prescribing and practice management platform, is a significant indirect competitor, especially in the provider workflow and clinical decision support space. It is used by over 30,000 healthcare professionals and emphasizes speed, compliance, and patient safety (The Intake). While Tebra focuses on practice efficiency and e-prescribing, Amalgam Rx’s strength lies in digital health solutions that integrate patient engagement and clinical data, making them complementary but distinct in their core offerings (The Intake). Tebra’s large user base and focus on practice management give it a substantial market share advantage in the provider segment, contrasting with Amalgam Rx’s broader digital health ecosystem approach.
Product & Pricing
Amalgam Rx Product and Pricing Intelligence
The company's recent financial activities include raising a $20 million credit investment from Catalio Capital in September 2025, indicating ongoing investment in expanding their platform capabilities. Although specific pricing tiers and free versus paid features are not publicly detailed, Amalgam Rx’s platform emphasizes modularity and enterprise scalability, suggesting tiered offerings tailored to different organizational needs (Amalgam Rx). As of March 2026, the company continues to evolve its solutions, focusing on regulatory compliance and global scalability, but explicit current pricing plans or recent changes are not publicly available.
Ad Campaigns
Amalgam Rx Ad Campaigns
Amalgam Rx is currently running 292 ads across LinkedIn — 292 on LinkedIn. Explore Amalgam Rx's live ad creative, messaging, and the platforms they advertise on in the ad library — updated automatically by ForesightIQ.
See of Amalgam Rx's ads
Browse the live creative across Google, Meta & LinkedIn in the ad library
Hiring & Layoffs
Amalgam Rx Hiring and Layoffs
Recent hiring patterns suggest that Amalgam Rx is prioritizing roles related to digital health, AI, and clinical decision support, aligning with its strategy to enhance its platform and expand its market presence in health sciences and digital medicine (Amalgam Rx). The company’s recent funding rounds, including a $20 million credit investment from Catalio Capital in September 2025, further support its ongoing investment in growth and innovation (CNBC). Overall, their hiring patterns and financial activity signal a strategic focus on scaling their AI-powered healthcare solutions and strengthening their position in the digital health ecosystem.
Sources
Careers | Amalgam Rx
amalgamrx.com
Amalgam Rx – Funding, Valuation, Investors, News
o.parsers.vc
Fastest Growing Occupations - Bureau of Labor Statistics
bls.gov
The top 10 fastest-growing jobs in health care, according to BLS data
cnbc.com
Top 10 Highest-Paying Healthcare Jobs UK | Most in Demand
xpresshealth.co.uk
Amalgam Rx Employee Directory
leadiq.com
Amalgam Rx
fr.linkedin.com
Leadership
Amalgam Rx Management and Leadership Team
Regarding recent leadership changes, there are no reports of significant shifts or new hires at the C-suite level as of March 2026. The company's leadership team and board, which includes members like Sonny Vu and Jane Buus Laursen, continue to steer Amalgam Rx’s growth in digital health innovation (The Org). Overall, Amalgam Rx maintains a strong leadership foundation focused on leveraging real-world evidence and digital health technologies to transform healthcare delivery.
Financials
Amalgam Rx Financial Performance, Fundraising, M&A
Regarding mergers and acquisitions, there are no publicly available reports of recent M&A activity involving Amalgam Rx. The company's strategy appears focused on organic growth through product development and strategic partnerships within the healthcare and life sciences sectors. Its recent activity includes raising capital from notable investors such as Plug and Play Tech Center, which underscores its ongoing expansion efforts (Parsers VC). Overall, Amalgam Rx maintains a strong financial footing, supported by revenue generation, strategic funding, and continuous growth in its digital health and AI solutions.
Partnerships
Amalgam Rx Partnerships, Clients and Vendors
In addition, Amalgam Rx has expanded its partnership with Novo Nordisk to enhance diabetes management through the integration of Dose Check with connected insulin delivery devices, continuous glucose monitors, and electronic health records (EHRs). This strategic alliance involves product commercialization and an equity investment, emphasizing Amalgam’s role in digital health innovation (biopharmaapac.com).
Amalgam Rx’s ecosystem also includes collaborations with global life sciences companies, health plans, and providers, leveraging their modular AI-powered SaaMD platform and EHR solutions to support over 10 million patients worldwide. Their solutions are integrated into provider workflows to improve clinical decision-making, patient engagement, and care delivery, demonstrating their extensive ecosystem relationships (amalgamrx.com). Notably, their partnerships often involve integrating digital health products, clinical decision support tools, and AI technologies to optimize healthcare outcomes across multiple continents (ai-techpark.com).
Events
Amalgam Rx Event Participations
In addition, Amalgam Rx was a collaborator at the Becker’s Behavioral Health Summit on June 6, 2025, where they launched a Behavioral Health and Primary Care Innovation Collaborative, showcasing their engagement in behavioral health and primary care innovation events (beckersbehavioralhealth.com). They also partnered with Biolinq in October 2025 for a health-focused event, highlighting their ongoing involvement in industry collaborations and partnerships (markets.financialcontent.com).
Furthermore, Amalgam Rx's leadership, including President Chris Bergstrom, participated in the 2026 Congress on Healthcare Leadership, where they discussed the future of healthcare delivery and digital health strategies, emphasizing their role in thought leadership and industry discourse (congress.ache.org). These engagements demonstrate Amalgam Rx's active involvement in shaping and influencing the digital health landscape through various high-profile events.
Sources
HLTH Community Think Tank, Boston with Amalgam Rx and Novo ...
hlth.com
Amalgam Rx Launches Behavioral Health + Primary Care Innovation Collaborative at Becker’s Behavioral Health Summit
beckersbehavioralhealth.com
Upcoming Events - Amalgam Rx Partners with Biolinq -- Lighting Pathways to Better Health
markets.financialcontent.com
Digital Products | Amalgam Rx
amalgamrx.com
Privacy Policy | Amalgam Rx
amalgamrx.com
Amalgam Rx Launches Behavioral Health + Primary Care ...
beckersbehavioralhealth.com
Amalgam Rx secures $20M credit investment | MobiHealthNews
mobihealthnews.com
Amalgam Rx - LinkedIn
linkedin.com
Frequently Asked Questions
What does Amalgam Rx's $20 million credit investment from Catalio Capital in September 2025 signal about its growth strategy versus its current revenue scale?
The Catalio Capital credit facility suggests Amalgam Rx is using debt financing rather than dilutive equity rounds to fund expansion, which typically indicates management confidence in near-term cash generation. With estimated revenues ranging from $12.4 million (RocketReach) to $20.8 million (Growjo) annually and total disclosed funding of approximately $17.4 million in equity, a $20 million credit line is a meaningful acceleration instrument. The parallel product launches — including ElevmiTM with Otsuka and expanded Novo Nordisk integration — suggest the capital is earmarked for commercialization and platform scaling rather than R&D from scratch.
What does Amalgam Rx's hiring posture — no open roles listed but 1.8% headcount growth — tell us about their operational model and scaling approach?
The absence of posted roles alongside modest 1.8% year-over-year headcount growth (within a 51–200 employee band) suggests Amalgam Rx is scaling through strategic, targeted hiring rather than broad expansion, likely filling roles off-market or through referrals. This is consistent with a capital-efficient model for a company at their revenue scale — keeping fixed costs controlled while deploying the Catalio credit facility toward product and partnerships. The emphasis on AI, digital health, and clinical decision support roles in recent hiring aligns with their platform roadmap rather than signaling a sales or GTM hiring surge.
What does the expanded Novo Nordisk partnership — including equity investment and product commercialization — reveal about Amalgam Rx's go-to-market model?
The Novo Nordisk relationship, which combines product integration (Dose Check with connected insulin devices, CGMs, and EHRs) with an equity investment, reveals that Amalgam Rx pursues co-development and equity-linked commercial partnerships with large pharma rather than a direct-to-provider or direct-to-payer sales motion as its primary channel. This model — where a pharma partner co-invests and co-commercializes — de-risks distribution and provides validation from a global diabetes franchise leader. It also suggests Amalgam Rx's platform is designed to be embedded in brand-specific digital health programs, which limits standalone product visibility but deepens integration stickiness.
What does the launch of ElevmiTM with Otsuka Precision Health signal about Amalgam Rx's therapeutic area expansion beyond diabetes?
The ElevmiTM launch — an AI-powered caregiver support tool for Alzheimer's patients co-developed with Otsuka Precision Health — signals that Amalgam Rx is deliberately broadening beyond its diabetes and metabolic health roots into neurology and caregiver-facing applications. This follows the same pharma co-development model used with Novo Nordisk, suggesting a repeatable playbook: identify a large pharma partner with a disease-specific need, embed Medical-Grade AI into a branded digital support product, and commercialize jointly. The Becker's Behavioral Health Summit engagement in June 2025 and the launch of a Behavioral Health and Primary Care Innovation Collaborative further reinforce a multi-therapeutic-area ambition.
What does Amalgam Rx's co-sponsorship of the HLTH Community Think Tank with Novo Nordisk suggest about how they're positioning themselves to large pharma buyers?
Co-sponsoring the HLTH Community Think Tank in Boston alongside Novo Nordisk — an event focused on scaling digital health adoption for pharma, providers, and digital health innovators — positions Amalgam Rx as a thought-leadership peer to its pharma partners rather than a vendor to them. This is a deliberate signal to other large life sciences companies that Amalgam Rx operates at the strategic level of digital health deployment, not just product execution. For corp-dev and BD teams at pharma companies evaluating digital health partnerships, this visibility alongside a Tier-1 pharma validates Amalgam Rx's credibility in the space.
With BrightInsight and Sidekick Health as direct competitors, where does Amalgam Rx's competitive differentiation actually sit?
Amalgam Rx's differentiation appears to lie in its EHR integration depth and its Medical-Grade AI layer, which is positioned to support over 70 million clinical decisions across nearly 10 million patients — a scale claim that BrightInsight (which leans toward regulatory compliance infrastructure for biopharma) and Sidekick Health (which focuses on patient-facing behavioral therapeutics) do not prominently match. Amalgam Rx's modular SaMD platform sits at the intersection of clinical decision support and pharma-sponsored digital health, giving it a distinct niche from BrightInsight's medtech compliance play and Sidekick's consumer engagement model. However, its relatively small headcount (~49–200 employees) compared to enterprise competitors like Better (founded 1989, broader platform) is a scale risk in competitive bids.
What does the composition of Amalgam Rx's leadership team — a former BCG and WellDoc executive as President, a Chief Data Scientist and Head of AI, and a Chief Medical Officer — tell us about their strategic priorities?
The leadership bench reflects three deliberate strategic priorities: commercial scaling via pharma and health system channels (Chris Bergstrom, President, ex-BCG and WellDoc), clinical credibility for regulatory and provider market access (Suzanne Clough, CMO), and AI/data as a core product differentiator (Bharath Sudharsan, Chief Data Scientist and Head of AI). WellDoc experience in particular is notable — WellDoc pioneered prescription digital therapeutics — suggesting Bergstrom brings a reimbursement and pharma-partnership playbook directly relevant to Amalgam Rx's model. The combination signals a company building for enterprise pharma and health system buyers rather than consumer or DTC markets.
What does Amalgam Rx's October 2025 partnership with Biolinq suggest about their hardware-software integration direction?
The Biolinq partnership — Biolinq being a biosensor/continuous monitoring company — suggests Amalgam Rx is extending its platform to ingest and act on real-time physiological data streams, not just patient-reported or EHR data. This aligns with their Novo Nordisk work integrating Dose Check with continuous glucose monitors, indicating a broader strategy of becoming the AI and clinical decision layer on top of wearable and connected device data. For competitive positioning, this capability would be difficult for software-only competitors like Sidekick Health to replicate quickly and reinforces Amalgam Rx's Medical-Grade AI positioning.
Is Amalgam Rx's revenue base — estimated at $12–21 million annually after nearly a decade in market — a signal of deliberate capital efficiency or a growth ceiling concern?
The revenue range ($12.4M per RocketReach, up to $20.8M per Growjo) for a company founded in 2016 with ~$17.4 million in equity funding and a $20 million credit facility suggests Amalgam Rx has prioritized sustainable, partnership-driven growth over hypergrowth, but also raises legitimate questions about scalability given the time elapsed. The pharma co-development model generates revenue but can be lumpy and partner-dependent, which may explain the revenue range uncertainty. The Catalio credit facility and ongoing partnership expansions (Novo Nordisk, Otsuka, Biolinq) indicate the company believes it is entering a commercialization acceleration phase, but independent evidence of revenue inflection is not yet confirmed in available data.
What does Amalgam Rx's launch of a Behavioral Health and Primary Care Innovation Collaborative at Becker's in June 2025 signal about near-term product or partnership moves?
Launching a named collaborative at a major behavioral health summit is typically a precursor to either a formal product announcement in the behavioral health space or a structured BD effort to recruit health system and payer partners into a co-development or pilot cohort. Given Amalgam Rx's pattern — HLTH Think Tank with Novo Nordisk preceded the expanded diabetes partnership, Otsuka engagement preceded ElevmiTM — the Becker's Collaborative is likely a pipeline-building vehicle for a behavioral health or primary care product launch in 2025–2026. It also signals that behavioral health is a priority vertical expansion alongside their neurology (Alzheimer's/Otsuka) and metabolic (Novo Nordisk) programs.
What does the presence of Sonny Vu and Jane Buus Laursen on Amalgam Rx's board suggest about the company's strategic network and likely exit or partnership pathways?
Sonny Vu brings deep experience in connected devices and hardware-software health tech (co-founder of Misfit Wearables, acquired by Fossil Group; involved in multiple medtech ventures), which is consistent with Amalgam Rx's push into biosensor integration via Biolinq and connected device partnerships with Novo Nordisk. Jane Buus Laursen's background in the Novo Nordisk ecosystem (she has held senior Novo Nordisk roles) suggests the Novo Nordisk equity investment and partnership runs deeper than a commercial contract — it is board-level relationship infrastructure. This board composition makes a Novo Nordisk acquisition or deeper strategic lock-in a plausible long-term scenario, and positions Amalgam Rx within a pharma-aligned rather than pure VC-to-IPO exit trajectory.
Powered by ForesightIQ · Competitive intelligence from digital exhaust